This article is more than 5 years old. Information may no longer be current.

VIDEO: OASIS study shows patient selection essential in ocriplasmin for VMT

Issue: October 2016

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — At the American Academy of Ophthalmology meeting here, Pravin U. Dugel, MD, discusses 2-year results of the OASIS study of ocriplasmin for vitreo-macular traction.
“The key to this study is that a higher rate of success can be achieved with better patient selection, and no new safety signals were seen,” Dugel said.